Volume 27, Issue 5 (Iran South Med J 2025)
Iran South Med J 2025, 27(5): 394-408 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Khorshidi M, Manoochehri H, AAlikhani M, Ezatzadeh M. Identification of Key Hub Genes Associated with Breast Cancer Stem Cells to Overcome Therapy Resistance. Iran South Med J 2025; 27 (5) :394-408
URL: http://ismj.bpums.ac.ir/article-1-2142-en.html
URL: http://ismj.bpums.ac.ir/article-1-2142-en.html
1- Student Research Committee, Bushehr University of Medical Sciences, Bushehr, Iran
Department of Medical Biotechnology, School of Paramedicine, Bushehr University of Medical Sciences, Bushehr, Iran
2- The Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran ,Manoochehry.hamed@gmail.com
3- Department of Medical Biotechnology, School of Paramedicine, Bushehr University of Medical Sciences, Bushehr, Iran
Department of Medical Biotechnology, School of Paramedicine, Bushehr University of Medical Sciences, Bushehr, Iran
2- The Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran ,
3- Department of Medical Biotechnology, School of Paramedicine, Bushehr University of Medical Sciences, Bushehr, Iran
Abstract: (325 Views)
Background: Breast cancer is one of the most common and fatal malignancies in women. The presence of cancer stem cells (CSCs), which play a crucial role in metastasis, therapeutic resistance, and disease recurrence, presents a major treatment challenge. Identifying CSCs-specific therapeutic targets through systems biology approaches can lead to more effective treatment strategies
Materials and Methods: Three gene expression datasets related to breast cancer— GSE7513 (Cancer stem/non-stem cells), GSE15852 (tumor/normal tissues), and GSE76540 (doxorubicin resistant/sensitive cells)— were obtained from the GEO database. Data were analyzed using GEO2R, DAVID, STRING, and Cytoscape. Hub genes were identified based on network parameters (GSE7513 and GSE15852 datasets) and compared with differentially expressed genes in GSE76540. Additionally, gene expression levels, treatment response prediction, and drug–gene interactions were evaluated using TNMplot, ROC Plotter, and DGIdb.
Results: Gene expression data from the datasets included 1446, 344, and 1826 DEGs in GSE7513, GSE15852, and GSE76540, respectively. Comparative analysis between GSE7513 and GSE15852 identified 75 common DEGs. Protein– protein interaction network analysis output was three clusters and seven hub genes, four of them overlapped with DEGs in GSE76540. AGR2, GATA3, and KRT19 genes were selected based on TNM. KRT19 and GATA3 were associated with patients' response to treatment. According to the DGIdb, GATA3 is a potentially druggable target with existing therapeutic compounds.
Conclusion: This study suggests that GATA3 may serve as a biomarker for predicting treatment response and as a potential therapeutic target in breast cancer.
Materials and Methods: Three gene expression datasets related to breast cancer— GSE7513 (Cancer stem/non-stem cells), GSE15852 (tumor/normal tissues), and GSE76540 (doxorubicin resistant/sensitive cells)— were obtained from the GEO database. Data were analyzed using GEO2R, DAVID, STRING, and Cytoscape. Hub genes were identified based on network parameters (GSE7513 and GSE15852 datasets) and compared with differentially expressed genes in GSE76540. Additionally, gene expression levels, treatment response prediction, and drug–gene interactions were evaluated using TNMplot, ROC Plotter, and DGIdb.
Results: Gene expression data from the datasets included 1446, 344, and 1826 DEGs in GSE7513, GSE15852, and GSE76540, respectively. Comparative analysis between GSE7513 and GSE15852 identified 75 common DEGs. Protein– protein interaction network analysis output was three clusters and seven hub genes, four of them overlapped with DEGs in GSE76540. AGR2, GATA3, and KRT19 genes were selected based on TNM. KRT19 and GATA3 were associated with patients' response to treatment. According to the DGIdb, GATA3 is a potentially druggable target with existing therapeutic compounds.
Conclusion: This study suggests that GATA3 may serve as a biomarker for predicting treatment response and as a potential therapeutic target in breast cancer.
Keywords: Breast Neoplasm, Cancer Stem Cells, Chemoresistance, Systems Biology, Protein– Protein Interaction
Type of Study: Original |
Subject:
medical Genetics
Received: 2025/04/15 | Accepted: 2025/05/11 | Published: 2025/06/1
Received: 2025/04/15 | Accepted: 2025/05/11 | Published: 2025/06/1
References
1. Hajigholami S, Vaise Malekshahi Z. Nano Pack-aged Diblock and Curcumin: a New Approach Inor-der To Drug Resistance in Breast Cancer. Iran South Med J 2017; 19(6): 951–61. [Article]
2. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of inci-dence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74(3): 229-63. [DOI]
3. Pont M, Marqués M, Sorolla A. Latest therapeuti-cal approaches for triple-negative breast cancer: From preclinical to clinical research. Int J Mol Sci 2024; 25(24): 13518. [DOI]
4. Manoochehri H, Farrokhnia M, Sheykhhasan M, et al. Key target genes related to anti-breast cancer activity of ATRA: A network pharmacology, molec-ular docking and experimental investigation. Heli-yon 2024; 10(14): e34300. [DOI]
5. Manoochehri H, Asadi S, Tanzadehpanah H, et al. CDC25A is strongly associated with colorectal cancer stem cells and poor clinical outcome of patients. Gene Reports 2021; 25: 101415. 10. [DOI]
6. Wang L, Jin Z, Master RP, et al. Breast Cancer Stem Cells: Signaling Pathways, Cellular Interac-tions, and Therapeutic Implications. Cancers (Ba-sel) 2022; 14(13): 3287. [DOI]
7. Palomeras S, Ruiz-Martínez S, Puig T. Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance. Molecules. 2018; 23(9): 2193. [DOI]
8. Hillebrand LE, Reinheckel T. Impact of proteolysis on cancer stem cell functions. Biochimie 2019;1 66: 214-22. [DOI]
9. Chen J, Chen S, Zhuo L, et al. Regulation of cancer stem cell properties, angiogenesis, and vasculo-genic mimicry by miR-450a-5p/SOX2 axis in colo-rectal cancer. Cell Death Dis 2020; 11(3): 173. [DOI]
10. Manoochehri H, Sheykhhasan M, Samadi P, et al. System biological and experimental validation of miRNAs target genes involved in colorectal cancer radiation response. Gene Reports 2019; 17: 100540.10. [DOI]
11. Manoochehri H, Jalali A, Tanzadehpanah H, et al. Identification of key Gene Targets for Sensitizing Colorectal Cancer to Chemoradiation: an Integra-tive Network Analysis on Multiple Transcriptomics Data. J Gastrointest Cancer 2022; 53(3): 649-68. [DOI]
12. Çorbacıoğlu Ş K, Aksel G. Receiver operating char-acteristic curve analysis in diagnostic accuracy studies: A guide to interpreting the area under the curve value. Turk J Emerg Med 2023; 23(4): 195-8. [DOI]
13. Puckett Y, Patel P, Bokhari AA. Prednisone. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. [Article]
14. Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, et al. Doxorubicin pathways: Pharmacodynam-ics and adverse effects. Pharmacogenet Ge-nomics. 2011; 21(7): 440-6. [DOI]
15. Sharma H, Wadhwa R. Mercaptopurine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; [Article]
16. Johnson DB, Lopez MJ, Kelley B. Dexamethasone. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. [Article]
17. Hanoodi M, Mittal M. Methotrexate. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Pub-lishing; 2025: 32310574. [Article]
18. Nousari HC, Sragovich A, Kimyai-Asadi A, et al. Mycophenolate mofetil in autoimmune and in-flammatory skin disorders. J Am Acad Dermatol 1999;40(2): 265-8. [DOI]
19. Awosika AO, Below J, Das JM. Vincristine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. [Article]
20. Faruqi A, Tadi P. Cytarabine. In: StatPearls [Inter-net]. Treasure Island (FL): StatPearls Publishing; 2025. [Article]
21. Hegde VS, Nagalli S. Leucovorin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. [Article]
22. Fassas A, Anagnostopoulos A. The use of liposo-mal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma 2005; 46(6): 795-802. [DOI]
23. Voduc D, Cheang M, Nielsen T. GATA-3 expression in breast cancer has a strong association with es-trogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomarkers Prev 2008; 17(2): 365-73. [DOI]
24. Sharma P, Alsharif S, Bursch K, et al. Keratin 19 regulates cell cycle pathway and sensitivity of breast cancer cells to CDK inhibitors. Sci Rep. 2019; 9(1): 14650. [DOI]
25. Hosseinzadeh L, Kikhtyak Z, Laven-Law G, et al. The androgen receptor interacts with GATA3 to transcriptionally regulate a luminal epithelial cell phenotype in breast cancer. Genome Biol 2024; 25(1): 44. [DOI]
26. Raap M, Gierendt L, Werlein C, et al. Co-expression of transcription factor AP-2beta (TFAP2B) and GATA3 in human mammary epithelial cells with intense, apicobasal immunoreactivity for CK8/18. J Mol Histol. 2021; 52(6): 1257-64. [DOI]
27. Chen Y, Lin Y, Cui Z. Identification of adriamycin resistance genes in breast cancer based on mi-croarray data analysis. Transl Cancer Res 2020; 9(12): 7486-94. [DOI]
28. De Lara S, Parris TZ, Werner Rönnerman E, et al. GATA3 as a putative marker of breast cancer me-tastasis-A retrospective immunohistochemical study. Breast J 2018; 24(2): 184-8. [DOI]
29. Maneechotesuwan K, Yao X, Ito K, et al. Suppres-sion of GATA-3 nuclear import and phosphoryla-tion: a novel mechanism of corticosteroid action in allergic disease. PLoS Med 2009; 6(5): e1000076. [DOI]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
